According to Fierce Biotech this morning, the latest market rumor is that Henri Termeer, CEO of Genzyme, has contacted his counterpart at Takeda to determine their interest in buying Genzyme at $82 per share. Takeda for its part has expressed a desire to break into the US market in a bigger way. However, the company has been focused on oncology, CNS diseases and metabolic diseases. Genzyme's portfolio of orphan drugs for rare diseases may not be of strong interest or the best fit for them.
Posted by Bruce Lehr November 15th 2010.